Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malign...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Grandclément, C, Estoppey, C, Dheilly, E, Panagopoulou, M, Monney, T, Dreyfus, C, Loyau, J, Labanca, V, Drake, A, De Angelis, S, Rubod, A, Frei, J, Caro, LN, Blein, S, Martini, E, Chimen, M, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR, Menoret, E, Kervoelen, C, Pellat-Deceunynck, C, Moreau, P, Mbow, ML, Srivastava, A, Dyson, MR, Zhukovsky, EA, Perro, M, Sammicheli, S
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Springer Nature 2024

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Antzeko izenburuak